Vemurafenib

Generic Name
Vemurafenib
Brand Names
Zelboraf
Drug Type
Small Molecule
Chemical Formula
C23H18ClF2N3O3S
CAS Number
918504-65-1
Unique Ingredient Identifier
207SMY3FQT
Background

Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collab...

Indication

Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.
...

Associated Conditions
Metastatic Melanoma, Refractory Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Refractory Erdheim-Chester disease
Associated Therapies
-
Clinical Trials
Related News

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Peking University Shenzhen Hospital
Target Recruit Count
200
Registration Number
NCT06692491

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People with Hairy Cell Leukemia (HCL)

First Posted Date
2024-08-20
Last Posted Date
2024-10-02
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
86
Registration Number
NCT06561360
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Mayo Clinic Cancer Center, Rochester, Minnesota, United States

🇺🇸

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

and more 7 locations

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

First Posted Date
2024-06-04
Last Posted Date
2024-12-02
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
21
Registration Number
NCT06440850
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

First Posted Date
2023-03-14
Last Posted Date
2023-10-25
Lead Sponsor
Cancer Research UK
Target Recruit Count
30
Registration Number
NCT05768178
Locations
🇬🇧

Freeman Hospital, Newcastle, United Kingdom

🇬🇧

Southampton General Hospital, Southampton, United Kingdom

🇬🇧

Leeds General Infirmary, Leeds, United Kingdom

and more 14 locations

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

First Posted Date
2022-09-02
Last Posted Date
2024-11-12
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
1000
Registration Number
NCT05525858
Locations
🇰🇷

Soonchunhyang University Hospital Bucheon, Bucheon, Korea, Republic of

🇰🇷

Chungbuk National University Hospital, Chungju, Korea, Republic of

🇰🇷

Keimyung University Dongsan Hospital, Daegu, Korea, Republic of

and more 29 locations

HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

Phase 2
Recruiting
Conditions
Melanoma
Interventions
Drug: HL-085
Drug: Vemurafenib
First Posted Date
2022-03-02
Last Posted Date
2023-05-31
Lead Sponsor
Shanghai Kechow Pharma, Inc.
Target Recruit Count
104
Registration Number
NCT05263453
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

First Posted Date
2022-03-02
Last Posted Date
2024-05-14
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT05260684
Locations
🇺🇸

Pfizer Investigational Site, New York, New York, United States

SMMART Adaptive Clinical Treatment (ACT) Trial

Early Phase 1
Withdrawn
Conditions
Advanced Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Stage II Pancreatic Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Advanced Prostate Carcinoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Breast Carcinoma
Stage IV Ovarian Cancer AJCC v8
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Interventions
Drug: Alectinib
Drug: Alpelisib
Drug: Anastrozole
Biological: Atezolizumab
Biological: Bevacizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Capecitabine
Drug: Carboplatin
Drug: Cobimetinib
Drug: Entrectinib
Drug: Eribulin
Drug: Fulvestrant
Biological: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Drug: Irinotecan
Drug: Letrozole
Drug: Nab-paclitaxel
Drug: Niraparib
Drug: Olaparib
Drug: Paclitaxel
Drug: Palbociclib
Biological: Pertuzumab
Other: Quality-of-Life Assessment
Biological: Trastuzumab
Biological: Trastuzumab Emtansine
Drug: Vemurafenib
Drug: Vinorelbine
Drug: Vismodegib
First Posted Date
2022-02-14
Last Posted Date
2024-01-23
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT05238831

Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

Phase 2
Recruiting
Conditions
CRC
Interventions
Drug: HL-085
Drug: Vemurafenib
First Posted Date
2022-02-10
Last Posted Date
2023-05-31
Lead Sponsor
Shanghai Kechow Pharma, Inc.
Target Recruit Count
186
Registration Number
NCT05233332
Locations
🇨🇳

Beijing Oncology Hospital, Beijing, Beijing, China

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

First Posted Date
2021-12-16
Last Posted Date
2024-07-15
Lead Sponsor
Helsinki University Central Hospital
Target Recruit Count
250
Registration Number
NCT05159245
Locations
🇫🇮

Turku University Hospital Cancer Centre, Turku, Varsinais-Suomi, Finland

🇫🇮

Kuopio University Hospital, Kuopio, Finland

🇫🇮

Oulu University Hospital OYS Cancer Center, Oulu, Finland

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy